Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Annaliese Glover

Nurse Practitioner, Family Mansfield, TX Nurse Practitioner

NPI 1548618481 CMS profile 10643016

1021 Matlock Rd, Mansfield, TX 76063

Open in the dashboard

General payments

$16,986

1,034 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Annaliese Glover of Mansfield, TX is reported in the CMS Open Payments database as having received $16,986 across 1,034 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,675 292
2024 General $3,729 216
2023 General $4,468 265
2022 General $2,874 199
2021 General $1,240 62

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Annaliese Glover
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Annaliese Glover were reported at $4,675. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Annaliese Glover Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,240 $124 $35–$379 $132
2022 $2,874 $141 $44–$430 $149
2023 $4,468 $154 $49–$476 $160
2024 $3,729 $165 $51–$504 $164
2025 $4,675 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Pharmaceuticals, Inc $2,040 126 payments
  2. Neurocrine Biosciences, Inc. $1,900 96 payments
  3. Otsuka America Pharmaceutical, Inc. $1,593 131 payments
  4. ITI, Inc. $1,587 98 payments
  5. Alkermes, Inc. $1,585 63 payments
  6. Lundbeck LLC $1,289 74 payments
  7. AbbVie, Inc. $985 88 payments
  8. Axsome Therapeutics, Inc. $982 42 payments
  9. Teva Pharmaceuticals USA, Inc. $693 36 payments
  10. Noven Therapeutics, LLC $680 46 payments
  11. Other $3,654 234 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $16,937 1,033 payments
  2. Education $49 1 payment
Products named General payments · program years 2021–2025
  1. INGREZZA $1,900 96 payments
  2. SPRAVATO $1,668 98 payments
  3. LYBALVI Cns $1,570 62 payments
  4. CAPLYTA $1,218 79 payments
  5. REXULTI $1,151 103 payments
  6. ARISTADA Cns $1,070 49 payments
  7. ARISTADA Cns $1,070 49 payments
  8. LYBALVI Cns $839 31 payments
  9. ARISTADA Cns $745 32 payments
  10. ARISTADA Cns $745 32 payments
  11. Other $12,590 744 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

158

Median for Nurse Practitioner: 389

Drug cost

$10,182

Median for Nurse Practitioner: $21,885

Branded share of claims

18.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trintellix Vortioxetine Hydrobromide Brand 15 $7,497
Bupropion Xl Bupropion Hcl Brand 14 $796
Duloxetine Hcl Generic 38 $668
Clonazepam Generic 31 $338
Trazodone Hcl Generic 12 $325
Fluoxetine Hcl Generic 24 $269
Aripiprazole Generic 11 $198
Escitalopram Oxalate Generic 13 $92

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAPLYTA
$510 — —
REXULTI
$419 — —
SPRAVATO
$405 — —
INGREZZA
$379 — —
ARISTADA
$249 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

1,034 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record